Sex disparities in overall burden of disease among hiv-infected individuals in the veterans affairs healthcare system

Journal of General Internal Medicine

Volumn 28, Issue SUPPL.2, 2013, Pages

  Blackstock, Oni J ^a,c   Tate, Janet P ^b,c   Akgün, Kathleen M ^b,c   Crystal, Stephen ^d   Duggal, Mona ^c   Edelman, E Jennifer ^c   Gibert, Cynthia L ^e   Gordon, Kirsha S ^b   Rimland, David ^f   Rodriguez Barradas, Maria C ^g   Wang, Emily A ^c   Fiellin, David A ^c   Justice, Amy C ^b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Burden of illness; Health care disparities; HIV; Veterans; Women

Indexed keywords

ANTIRETROVIRUS AGENT; HEMOGLOBIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEALTH CARE SYSTEM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT CARE; PHARMACY; RETROSPECTIVE STUDY; SCORING SYSTEM; SEX DIFFERENCE; VACS INDEX SCORE; VETERAN;

ADULT; AGED; AGING; COHORT STUDIES; COST OF ILLNESS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS; VETERANS HEALTH;

EID: 84892904643     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-013-2346-z     Document Type: Article

References (40)

1. Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care J Acquir Immune Defic Syndr. 2000;24:475-82.
2. McNaghten AD, Hanson DL, Dworkin MS, Jones JL. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 2003;32:499-505.
3. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005;38:96-103.
4. Hirschhorn LR, McInnes K, Landon BE, et al. Gender differences in quality of HIV care in Ryan White CARE Act-funded clinics. Womens Health Issues. 2006;16:104-12.
5. Meditz AL, MaWhinney S, Allshouse A, et al. Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis. 2011;203:442-51.
6. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145:397-406.
7. Lemly DC, Shepherd BE, Hulgan T, et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis. 2009;199:991-8.
8. Mrus JM, Williams PL, Tsevat J, Cohn SE, Wu AW. Gender differences in health-related quality of life in patients with HIV/AIDS. Qual Life Res. 2005;14:479-91.
9. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377-81.
10. Turner BJ, Laine C, Cosler L, Hauck WW. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med. 2003;18:248-57.
11. Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med. 2004;19:1111-7.
12. Delgado J, Heath KV, Yip B, et al. Highly active antiretroviral therapy: Physician experience and enhanced adherence to prescription refill. Antivir Ther. 2003;8:471-8.
13. Department of Veterans Affairs. National HIV/AIDS Strategy Operation Plan. 2011. Available at: Http://www.aids.gov/federal-resources/policies/ national-hiv-aids-strategy/nhas-operational-plan-va.pdf. Accessed on January 7, 2012.
14. Department of Veterans Affairs. The State of Care for Veterans with HIV/AIDS. 2009. Available at: Http://www.hiv.va.gov/provider/state-of-care/ index.asp. Accessed on January 7, 2012.
15. Duggal M, Goulet JL, Womack J, et al. Comparison of outpatient health care utilization among returning women and men veterans from Afghanistan and Iraq. BMC Health Serv Res. 2010;10:175.
16. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a "virtual" cohort using the National VA Health Information System. Med Care. 2006;44:S25-30.
17. Justice AC, Freiberg MS, Tracy R, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV Clin Infect Dis. 2012;54:984-94.
18. Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined prognostic index for survival in HIV infection: The role of 'non-HIV' biomarkers. HIV Med. 2010;11:143-51.
19. Tate JP, Justice AC, Hughes MD, et al. The VACS Index: An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS 2012. Epub ahead of print. PMID 23095314.
20. Justice A, Modur S, Tate J, et al. Predictive accuracy of the Veterans Aging Cohort Study (VACS) Index for Mortality with HIV Infection: A North American Cross Cohort Analysis. J Acquir Immune Defic Syndr 2012. Epub ahead of print. PMID: 23187941.
21. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565-74. discussion 75-7.
22. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988;26:814-23.
23. Hirsch JD, Gonzales M, Rosenquist A, Miller TA, Gilmer TP, Best BM. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS. J Manag Care Pharm. 2011;17:213-23.
24. Moore AL, Sabin CA, Johnson MA, Phillips AN. Gender and clinical outcomes after starting highly active antiretroviral treatment: A cohort study. J Acquir Immune Defic Syndr. 2002;29:197-202.
25. Giordano TP, White AC Jr, Sajja P, et al. Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr. 2003;32:399-405.
26. Finkel DG, John G, Holland B, Slim J, Smith SM. Women have a greater immunological response to effective virological HIV-1 therapy. AIDS. 2003;17:2009-11.
27. Moore AL, Mocroft A, Madge S, et al. Gender differences in virologic response to treatment in an HIV-positive population: A cohort study. J Acquir Immune Defic Syndr. 2001;26:159-63.
28. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS. 2001;15:2251-7.
29. Centers for Disease Control and Prevention. Vital Signs: HIV prevention through care and treatment - United States. MMWR Morb Mortal Wkly Repo 2011;60:1618-123.
30. Moore AL, Kirk O, Johnson AM, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: The gender issue revisited. J Acquir Immune Defic Syndr. 2003;32:452-61.
31. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet. 2002;360:119-29.
32. Justice AC, Erdos J, Brandt C, Conigliaro J, Tierney W, Bryant K. The Veterans Affairs Healthcare System: A unique laboratory for observational and interventional research. Med Care. 2006;44:S7-12.
33. Justice AC, Dombrowski E, Conigliaro J, et al. Veterans Aging Cohort Study (VACS): Overview and description. Med Care. 2006;44:S13-24.
34. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-96.
35. Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis. 2008;47:542-53.
36. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172.
37. Washington DL, Bean-Mayberry B, Riopelle D, Yano EM. Access to care for women veterans: Delayed healthcare and unmet need. J Gen Intern Med. 2011;26(Suppl 2):655-61.
38. Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M. Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: Results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr. 2008;47:441-8.
39. Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf. 2005;28:1075-83.
40. Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med. 2003;11:55-9.